Webinar: Office-Based Induction of Buprenorphine-Naloxone

May 30, 2017 webinar - Office-Based Induction of Buprenorphine-Naloxone

- Selecting appropriate pharmacological and psychosocial treatment options for opioid use based on safety and effectiveness evidence, as well as individual patient needs, circumstances, and preferences
- Understanding the unique pharmacology of methadone, buprenorphine/naloxone, and slow-release oral morphine, and the comparative efficacy and safety of these options
- Understanding recent regulatory changes that allow all physicians in BC to prescribe buprenorphine/naloxone

Dr. Kit Fairgrieve, MD, is a family doctor at St. Paul’s Hospital. Currently, Dr. Fairgrieve is Associate Fellowship Director of the St. Paul’s Hospital Goldcorp Addiction Medicine Fellowship at the BC Centre on Substance Use (BCCSU), as well as a Canada Addiction Medicine Research Fellow with the BCCSU. His interests include clinical addiction medicine, medical education, and addiction research.

The Provincial Guidelines for the Clinical Management of Opioid Use Disorder are available here:
http://www.bccsu.ca/care-guidance-publications/

Видео Webinar: Office-Based Induction of Buprenorphine-Naloxone канала British Columbia Centre on Substance Use